Baxter International Inc. (NYSE:BAX) Shares Bought by Anchor Investment Management LLC

Anchor Investment Management LLC boosted its stake in shares of Baxter International Inc. (NYSE:BAX) by 79.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 20,463 shares of the medical instruments supplier’s stock after purchasing an additional 9,043 shares during the period. Anchor Investment Management LLC’s holdings in Baxter International were worth $597,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. CKW Financial Group boosted its stake in shares of Baxter International by 19.3% in the fourth quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock worth $77,000 after buying an additional 425 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in Baxter International by 5.8% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 13,618 shares of the medical instruments supplier’s stock worth $397,000 after purchasing an additional 752 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International during the 4th quarter worth approximately $26,000. Riverview Trust Co increased its holdings in shares of Baxter International by 5,488.2% during the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 933 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of Baxter International by 61.2% in the 4th quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 1,541 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Stock Down 1.7 %

Shares of NYSE:BAX opened at $27.89 on Wednesday. The business has a fifty day moving average of $32.61 and a two-hundred day moving average of $32.81. Baxter International Inc. has a 52-week low of $26.25 and a 52-week high of $41.18. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The stock has a market cap of $14.30 billion, a P/E ratio of -21.79, a PEG ratio of 0.93 and a beta of 0.64.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.67 billion. On average, research analysts expect that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Friday, February 28th were given a $0.17 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.68 annualized dividend and a yield of 2.44%. Baxter International’s dividend payout ratio (DPR) is -53.13%.

Analyst Upgrades and Downgrades

BAX has been the topic of several analyst reports. The Goldman Sachs Group assumed coverage on shares of Baxter International in a research report on Wednesday, February 26th. They set a “buy” rating and a $42.00 price target on the stock. Barclays raised their target price on Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. Argus upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. dropped their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Baxter International has a consensus rating of “Hold” and an average target price of $38.56.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.